News

Press Releases

Aug 30, 2004

Mylan Withdraws Lawsuit in Order to Consider Additional Authorized Generics Claims
Aug 30, 2004

Mylan Reports Positive Study on Nebivolol Demonstrating Nebivolol Reduces the Risk of All Cause Mortality and Cardiovascular Hospitalization in Elderly Heart Failure Patients as Reported at the ESC
Aug 23, 2004

Mylan Receives FDA Approval for Metoprolol Tartrate and Hydrochlorothiazide Tablets

Mylan Also Announces Tentative Approval for Cetirizine Hydrochloride Tablets and Sertraline Hydrochloride Tablets
Aug 20, 2004

Mylan Comments on Yesterday's Trading Activity
Aug 19, 2004

FTC Grants Early Termination for Stock Purchase By Icahn
Aug 18, 2004

Mylan Seeks Immediate Appeal on Fentanyl Ruling
Jul 29, 2004

Mylan Receives FDA Approval for Fluconazole Tablets
Jul 26, 2004

Mylan Reports First Quarter Earnings - Record First Quarter Revenues Reported

Financial Highlights:
Jul 26, 2004

Mylan Laboratories to Acquire King Pharmaceuticals

$4 Billion Stock-For-Stock Transaction To Create New Leader in Specialty Pharmaceutical Industry
Jul 14, 2004

Mylan's Levothyroxine Sodium Tablets Approved as a Generic Equivalent to Levoxyl®
Jul 2, 2004

Mylan Enters Into a Settlement and License Agreement Ending Paclitaxel Litigation
Jul 1, 2004

Mylan's NDA for Nebivolol Accepted for FDA Review
Jun 30, 2004

Mylan Submits a Supplement to Its Citizens Petition Regarding Authorized Generics to the FDA
Jun 29, 2004

Mylan Names Margaret McKenna Chief Business Development Officer
Jun 28, 2004

Mylan Nominates Rod Piatt to its Board of Directors
Jun 25, 2004

Mylan Receives $37.5 Million and Settles All Outstanding Disputes With Schwarz Pharma's KUDCo and Related Parties
Jun 24, 2004

Mylan Receives FDA Approval for Levothyroxine Sodium Tablets
Jun 23, 2004

Mylan Sues FDA for Injunction Against Fentanyl Ruling
Jun 22, 2004

Mylan Laboratories Appoints Michael Marquard President of Mylan Bertek Pharmaceuticals
Jun 17, 2004

Mylan Declares Quarterly Cash Dividend
Jun 15, 2004

Mylan Announces Name Change for its Branded Products Subsidiary to Mylan Bertek
Jun 10, 2004

Mylan Receives FDA Approval for Ciprofloxacin Tablets
May 11, 2004

Mylan Reports Record EPS, Revenues and Net Earnings for Fiscal 2004

Annual Financial Highlights: * Record diluted earnings per share of $1.21 compared to $0.96 in the prior fiscal year. * Net revenues increased 8% to a record $1.37 billion. * Net earnings increased 23% to a record $334.6 million.
May 6, 2004

Mylan Receives Tentative Approval for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release Tablets
May 5, 2004

Mylan Submits New Drug Application for Nebivolol

Show per page

Mylan: Seeing is Believing

You are leaving Mylan.com

By clicking Continue below you are leaving Mylan.com and going to a third-party site.

Continue

Go back